Evolving Treatments in Hepatocellular Carcinoma: Updates from ASCO GI 2024

A panel of medical experts discuss key highlights from ASCO GI 2024 surrounding the hepatocellular carcinoma (HCC) treatment landscape.

EP. 1: Evolving Treatments in Hepatocellular Carcinoma: Updates from ASCO GI 2024

February 26th 2024

Anthony El-Khoueiry, MD, opens the discussion by defining the current prevalence of hepatocellular carcinoma (HCC).

EP. 2: Utilizing Interventional Radiology and Liver-directed Therapies

February 26th 2024

Mechanism of action for liver-directed therapies in HCC are illustrated by Anne Covey, MD, an interventional radiologist.

EP. 3: Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC

March 4th 2024

Michael Morse, MD, establishes his criteria for implementing TACE versus systemic therapy in HCC treatment.

EP. 4: EMERALD-1 Study: Significance as Presented at ASCO GI 2024

March 4th 2024

Rachna Shroff, MD, MS, FASCO, highlights the prominence of the EMERALD-1 study for patients with HCC.

EP. 5: EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies

March 11th 2024

Drs Gong and Covey emphasize the impact of TACE + durvalumab ± bevacizumab combination therapy surrounding HCC treatment strategy.

EP. 6: IMBrave-050 Study Overview

March 11th 2024

Dr Shroff breaks down the combination of atezolizumab and bevacizumab as outlined by the IMBrave-050 study.

EP. 7: Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab

March 18th 2024

Medical experts provide insight into managing treatment of advanced HCC through the lens of a patient profile.

EP. 8: HIMALAYA Study in Advanced Stage HCC

March 18th 2024

A comprehensive discussion of the HIMALAYA study, evaluating the STRIDE regimen of durvalumab plus tremelimumab in first-line treatment for advanced HCC.

EP. 9: Establishing Optimal HCC Treatment Strategy

March 25th 2024

Anwaar Saeed, MD, provides comprehensive insight into the HCC treatment selection process.

EP. 10: IMBrave150 Study Overview

March 25th 2024

Dr Gong breaks down the structure and key takeaways from the IMBrave150 study.

EP. 11: HCC Treatment Strategy Driven by Real-World Evidence

April 1st 2024

Real-world evidence (RWE) provides critical knowledge for providers constructing a treatment regimen for patients diagnosed with hepatocellular carcinoma.

EP. 12: Combining Liver-directed and Systemic Therapies in HCC

April 8th 2024

The impact of compounding liver-directed and systemic therapies in HCC management is discussed by Drs Morse and Covey.

EP. 13: Patient Profile 2: Patient Progression After Frontline HCC Therapy

April 8th 2024

Drs Saeed and Shroff discuss the next patient profile, focusing on HCC treatment strategies following disease progression after first-line therapy.

EP. 14: CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape

April 8th 2024

Key opinion leaders share their takeaways from the CARES-310 trial and its impact on their treatment approach in HCC management.

EP. 15: REGONEXT Study: Driving Second-line HCC Treatment Strategy

April 15th 2024

Dr Morse discusses key takeaways from the REGONEXT study presented at ASCO GI 2024.

EP. 16: Trajectory of Evolving HCC Treatment Landscape

April 15th 2024

The expert panelists provide their final insights surrounding the future of HCC treatment management.